CSTL Stock Overview
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus, uveal melanoma, and mental health conditions.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Castle Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.51 |
| 52 Week High | US$26.70 |
| 52 Week Low | US$9.26 |
| Beta | 0.92 |
| 1 Month Change | -9.63% |
| 3 Month Change | -10.22% |
| 1 Year Change | -11.92% |
| 3 Year Change | -71.34% |
| 5 Year Change | n/a |
| Change since IPO | -8.83% |
Recent News & Updates
Recent updates
Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects
Jan 27
Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans
Oct 31Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive
Jun 13Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)
Aug 14Castle Biosciences Q2 2022 Earnings Preview
Aug 08Is There Now An Opportunity In Castle Biosciences, Inc. (NASDAQ:CSTL)?
Aug 05Estimating The Intrinsic Value Of Castle Biosciences, Inc. (NASDAQ:CSTL)
Jun 06Shareholder Returns
| CSTL | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 1.6% | 0.6% | 1.0% |
| 1Y | -11.9% | 2.2% | 21.9% |
Return vs Industry: CSTL underperformed the US Healthcare industry which returned 3.4% over the past year.
Return vs Market: CSTL underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| CSTL volatility | |
|---|---|
| CSTL Average Weekly Movement | 10.9% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CSTL's share price has been volatile over the past 3 months.
Volatility Over Time: CSTL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 610 | Derek Maetzold | castlebiosciences.com |
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett’s esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder.
Castle Biosciences, Inc. Fundamentals Summary
| CSTL fundamental statistics | |
|---|---|
| Market cap | US$538.22m |
| Earnings (TTM) | -US$57.47m |
| Revenue (TTM) | US$219.79m |
2.4x
P/S Ratio-9.4x
P/E RatioIs CSTL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CSTL income statement (TTM) | |
|---|---|
| Revenue | US$219.79m |
| Cost of Revenue | US$44.98m |
| Gross Profit | US$174.81m |
| Other Expenses | US$232.27m |
| Earnings | -US$57.47m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -2.08 |
| Gross Margin | 79.53% |
| Net Profit Margin | -26.15% |
| Debt/Equity Ratio | 0% |
How did CSTL perform over the long term?
See historical performance and comparison